<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00308555</url>
  </required_header>
  <id_info>
    <org_study_id>CC # 064</org_study_id>
    <secondary_id>1R21DA020831-01</secondary_id>
    <nct_id>NCT00308555</nct_id>
  </id_info>
  <brief_title>Opioid and Cannabinoid Pharmacokinetic Interactions</brief_title>
  <official_title>Opioid and Cannabinoid Pharmacokinetic Interactions: A Pilot Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of California, San Francisco</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute on Drug Abuse (NIDA)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of California, San Francisco</source>
  <brief_summary>
    <textblock>
      We are conducting a study to assess whether smoking marijuana affects the safety of
      prescribed opioids in patients treated for chronic pain. This study will assess whether
      smoking cannabis affects the absorption, distribution, metabolism and excretion of widely
      used opioid analgesics. We propose to do this by investigating the effects of smoked cannabis
      in subjects prescribed morphine or oxycodone for chronic pain. We will also assess the
      clinical safety of cannabinoids and these opioids by monitoring the short-term side effects
      associated with combined therapy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Chronic pain conditions remain problematic, especially in patients with cancer. Although
      opioids are effective analgesics, dose-limiting side effects in the form of sedation, nausea
      and vomiting, and fear of dependence often limit their use at higher - and possibly more
      effective - doses. Of particular interest, however, is the potential for greater than
      additive analgesic effect of cannabinoids and opioids in combination that would allow for
      opioid analgesic effect to be achieved at lower dosages than are necessary alone, which could
      overcome problems with both tolerance and side effects for both drug classes. Unfortunately,
      safety data on the combination in humans does not exist at this time and needs to be
      obtained. As increasing numbers of patients with chronic pain may turn to cannabis to augment
      the effects of their opioid analgesics, data on potential pharmacokinetic interactions and
      clinical safety of the combinations should be evaluated in a controlled clinical research
      setting.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2006</start_date>
  <completion_date type="Actual">March 2009</completion_date>
  <primary_completion_date type="Actual">March 2009</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Disposition Kinetics of Morphine and Oxycodone Before and After Cannabis Use</measure>
    <time_frame>Day 1, Day 5</time_frame>
    <description>Pharmacokinetics are measured on Day 1, prior to cannabis use, and again on Day 5, following cannabis use on Days 2, 3, and 4.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Pain</condition>
  <arm_group>
    <arm_group_label>Cannabis</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cannabis</intervention_name>
    <arm_group_label>Cannabis</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Ongoing analgesic therapy with either oxycodone hydrochloride (OxyContin) or morphine
             sulfate (MS Contin) every 12 hours for chronic pain.

          2. Eligible subjects will be ≥ 18 years of age with a diagnosis of chronic pain and an
             estimated survival of greater than six months.

          3. Subjects must be on a stable dose of opioid medication for at least 2 weeks before
             enrollment.

          4. Current other analgesic medications will be maintained during the study. The subject
             must have been on a stable medication regimen for at least 2 weeks.

          5. The following laboratory parameters documented within 45 days prior to study entry:

               -  Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 5 X upper
                  limit of normal (ULN)

               -  Total bilirubin ≤ 2 X ULN

               -  Creatinine ≤ 2.0 mg/dL (177 µmol/L)

          6. All men and women in this study must agree to use adequate birth control during this
             study. Acceptable barrier birth control methods are a male condom, female condom,
             diaphragm, or intra-uterine (IUD).

          7. All women of reproductive potential (who have not reached menopause or undergone
             hysterectomy, oophorectomy, or tubal ligation) must have a negative urine b-HCG
             pregnancy test performed before initiating the protocol-specified medication.

          8. Prior history of use of marijuana. Subjects must have smoked marijuana on at least 6
             occasions in their lifetime prior to enrollment.

          9. Able to understand and follow the instructions of the investigator, including
             completing the pain intensity rating scales.

         10. Karnofsky Performance Score &gt;60.

         11. Able and willing to provide informed consent.

        Exclusion Criteria:

          1. Severe coronary artery disease, uncontrolled hypertension, cardiac ventricular
             conduction abnormalities, or orthostatic mean blood pressure drop greater than 24
             mmHg, severe chronic obstructive pulmonary disease.

          2. History of renal or hepatic failure.

          3. Evidence of hepatic, hematological or renal dysfunction based on judgment of
             physician.

          4. Active substance abuse (e.g., alcohol or injection drugs).

          5. Use of smoked marijuana within 30 days of enrollment verified with a urine THC level.

          6. Neurologic dysfunction or psychiatric disorder severe enough to interfere with
             assessment of pain or sensory systems.

          7. Current use of smoked tobacco products or a confirmed cotinine level.

          8. Women who are pregnant or breast-feeding may not take part in this study.

          9. Unable to read or speak English.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Donald I Abrams, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California, San Francisco</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Community Consortium</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 27, 2006</study_first_submitted>
  <study_first_submitted_qc>March 27, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 29, 2006</study_first_posted>
  <results_first_submitted>May 23, 2013</results_first_submitted>
  <results_first_submitted_qc>May 28, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">July 22, 2013</results_first_posted>
  <last_update_submitted>October 26, 2016</last_update_submitted>
  <last_update_submitted_qc>October 26, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 9, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Cannabis</keyword>
  <keyword>Morphine</keyword>
  <keyword>Oxycodone</keyword>
  <keyword>Marijuana</keyword>
  <keyword>chronic pain</keyword>

  <clinical_results>

    <participant_flow>
      <recruitment_details>315 participants were screened, via phone and e-mail, between January 2007 and February 2009. 24 subjects were enrolled, 13 taking morphine and 11 taking oxycodone.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>MS Contin</title>
          <description>Patients using morphine sulfate (MS Contin) every 12 hours for chronic pain were administered vaporized cannabis (3.96% delta 9-THC) equivalent to one 0.9 g cigarette on the following schedule: 20:00 on Day 1, 08:00/14:00/20:00 on Days 2 through 4, and 08:00 on Day 5.</description>
        </group>
        <group group_id="P2">
          <title>Oxycontin</title>
          <description>Patients using oxycodone hydrochloride (OxyContin) every 12 hours for chronic pain were administered vaporized cannabis (3.96% delta 9-THC) equivalent to one 0.9 g cigarette on the following schedule: 20:00 on Day 1, 08:00/14:00/20:00 on Days 2 through 4, and 08:00 on Day 5.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
                <participants group_id="P2" count="11"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="11"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>MS Contin</title>
          <description>Patients using morphine sulfate (MS Contin) every 12 hours for chronic pain</description>
        </group>
        <group group_id="B2">
          <title>Oxycontin</title>
          <description>Patients using oxycodone hydrochloride (OxyContin)every 12 hours for chronic pain</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="13"/>
            <count group_id="B2" value="11"/>
            <count group_id="B3" value="24"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="24"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="42.9" spread="7.4"/>
                    <measurement group_id="B2" value="47.1" spread="11.8"/>
                    <measurement group_id="B3" value="45.1" spread="10.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="12"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Mean opioid dose, twice daily</title>
          <description>Baseline medication use</description>
          <units>mg</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="62" lower_limit="10" upper_limit="100"/>
                    <measurement group_id="B2" value="53" lower_limit="10" upper_limit="120"/>
                    <measurement group_id="B3" value="58" lower_limit="10" upper_limit="120"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Disposition Kinetics of Morphine and Oxycodone Before and After Cannabis Use</title>
        <description>Pharmacokinetics are measured on Day 1, prior to cannabis use, and again on Day 5, following cannabis use on Days 2, 3, and 4.</description>
        <time_frame>Day 1, Day 5</time_frame>
        <population>The number was determined by the number of participants completing both Day 1 and Day 5 procedures.</population>
        <group_list>
          <group group_id="O1">
            <title>MS Contin</title>
            <description>Participants on morphine treatment</description>
          </group>
          <group group_id="O2">
            <title>Oxycodone</title>
            <description>Participants on oxycodone treatment</description>
          </group>
        </group_list>
        <measure>
          <title>Disposition Kinetics of Morphine and Oxycodone Before and After Cannabis Use</title>
          <description>Pharmacokinetics are measured on Day 1, prior to cannabis use, and again on Day 5, following cannabis use on Days 2, 3, and 4.</description>
          <population>The number was determined by the number of participants completing both Day 1 and Day 5 procedures.</population>
          <units>Geometric Mean Ratio</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Time to maximum concentration (Tmax)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.64" lower_limit="-1.01" upper_limit="4.30"/>
                    <measurement group_id="O2" value="-1.11" lower_limit="-3.66" upper_limit="1.43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Maximum concentration (Cmax)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.9" lower_limit="0.85" upper_limit="0.95"/>
                    <measurement group_id="O2" value="0.99" lower_limit="0.89" upper_limit="1.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Area under plasma concentration-time curve (AUC)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.95" lower_limit="0.84" upper_limit="1.05"/>
                    <measurement group_id="O2" value="0.94" lower_limit="0.84" upper_limit="1.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>MS Contin</title>
          <description>Patients using morphine sulfate (MS Contin) every 12 hours for cancer pain</description>
        </group>
        <group group_id="E2">
          <title>Oxycontin</title>
          <description>Patients using oxycodone hydrochloride (OxyContin)every 12 hours for cancer pain</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Small number of participants, powered to detect a 25% change in AUC(12).Further research is needed to determine how cannabis delivery systems other than vapor affect metabolism of opioids and other drugs.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Dr. Donald I. Abrams</name_or_title>
      <organization>UCSF/San Francisco General Hospital</organization>
      <phone>415-476-4082 ext 444</phone>
      <email>dabrams@hemeonc.ucsf.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

